Chi-Med (Hutchison China MediTech) and AstraZeneca presented positive safety and efficacy data of their partnered drug, the c-MET inhibitor savolitinib. Savolitinib was administered together with one of two AstraZeneca drugs — Tagrisso® (osimertinib) or Iressa® (gefitinib) — in two Phase Ib/II proof-of-concept trials in patients with non-small cell lung cancer. The patients had failed an earlier first-line treatment with an EGFR inhibitor. The most advanced savolitinib study is a recently started Phase III trial as a first-line treatment in patients with papillary renal cell carcinoma.
Source: China Biotoday
